BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 31905752)

  • 1. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
    Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31905752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of
    Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
    Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
    Nanni C; Zamagni E; Farsad M; Castellucci P; Tosi P; Cangini D; Salizzoni E; Canini R; Cavo M; Fanti S
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):525-31. PubMed ID: 16453155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review.
    van Lammeren-Venema D; Regelink JC; Riphagen II; Zweegman S; Hoekstra OS; Zijlstra JM
    Cancer; 2012 Apr; 118(8):1971-81. PubMed ID: 21887677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
    Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
    Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
    Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
    Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
    Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of FDG PET in the staging of multiple myeloma.
    Vicentini JRT; Bredella MA
    Skeletal Radiol; 2022 Jan; 51(1):31-41. PubMed ID: 33813607
    [No Abstract]   [Full Text] [Related]  

  • 10. PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma.
    Seval GC; Ozkan E; Beksac M
    PET Clin; 2019 Jul; 14(3):369-381. PubMed ID: 31084776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma.
    Nanni C; Zamagni E
    PET Clin; 2019 Jul; 14(3):383-389. PubMed ID: 31084777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.
    Bailly C; Leforestier R; Jamet B; Carlier T; Bourgeois M; Guérard F; Touzeau C; Moreau P; Chérel M; Kraeber-Bodéré F; Bodet-Milin C
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving role of FDG PET/CT in multiple myeloma imaging and management.
    Agarwal A; Chirindel A; Shah BA; Subramaniam RM
    AJR Am J Roentgenol; 2013 Apr; 200(4):884-90. PubMed ID: 23521465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of
    Basha MAA; Hamed MAG; Refaat R; AlAzzazy MZ; Bessar MA; Mohamed EM; Ahmed AF; Tantawy HF; Altaher KM; Obaya AA; Afifi AHM
    Jpn J Radiol; 2018 Jun; 36(6):382-393. PubMed ID: 29671193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positron emission tomography/computed tomography (PET/CT) in multiple myeloma].
    Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
    Radiologe; 2022 Jan; 62(1):20-29. PubMed ID: 34921323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
    Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Multiple Myeloma.
    Murtazaliev S; Rowe SP; Sheikhbahaei S; Werner RA; Sólnes LB
    PET Clin; 2024 Apr; 19(2):249-260. PubMed ID: 38199914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma.
    Kumar S; Glazebrook KN; Broski SM
    PET Clin; 2019 Jul; 14(3):391-403. PubMed ID: 31084778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of Magnetic Resonance Imaging and [
    Moreau P; Attal M; Caillot D; Macro M; Karlin L; Garderet L; Facon T; Benboubker L; Escoffre-Barbe M; Stoppa AM; Laribi K; Hulin C; Perrot A; Marit G; Eveillard JR; Caillon F; Bodet-Milin C; Pegourie B; Dorvaux V; Chaleteix C; Anderson K; Richardson P; Munshi NC; Avet-Loiseau H; Gaultier A; Nguyen JM; Dupas B; Frampas E; Kraeber-Bodere F
    J Clin Oncol; 2017 Sep; 35(25):2911-2918. PubMed ID: 28686535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.